948264.fig.002a
(a)
948264.fig.002b
(b)
948264.fig.002c
(c)
948264.fig.002d
(d)
948264.fig.002e
(e)
948264.fig.002f
(f)
948264.fig.002g
(g)
948264.fig.002h
(h)
Figure 2: Persistent detection of membranous staining for beta-catenin (a)–(d) and sporadic nuclear staining for beta-catenin (e)–(h). Membranous expression of the study marker was more observable in the lip and palate carcinomas (M, ) (a), in <2 cm tumor ( ) (b), and in well-differentiated cancers ( ) (c), in early stage (St I) tumours ( ) (d). Sporadic nuclear positivity for beta-catenin was more observable in <2 cm tumor ( ) (e), in early stage (St I) tumours ( ) (f), without nodal metastases (N0) ( ) (g), and with a better clinical followup ( ) (h).